IL36RN mutations define a severe autoinflammatory phenotype of generalized pustular psoriasis - 03/04/15
Doi : 10.1016/j.jaci.2014.09.043
Safia Hussain, BSc a, Dorottya M. Berki, BSc a, Siew-Eng Choon, MRCP b, A. David Burden, MD, FRCP c, Michael H. Allen, PhD a, Juan I. Arostegui, MD, PhD d, Antonio Chaves, MD e, Michael Duckworth a, Alan D. Irvine, MD f, g, Maja Mockenhaupt, MD, PhD h, Alexander A. Navarini, MD, PhD a, i, Marieke M.B. Seyger, MD, PhD j, Pere Soler-Palacin, MD, PhD k, Christa Prins, MD l, Laurence Valeyrie-Allanore, MD m, M. Asuncion Vicente, MD n, Richard C. Trembath, FMedSci o, Catherine H. Smith, MD, FRCP a, Jonathan N. Barker, MD, FRCP a, ∗ 
, Francesca Capon, PhD a, ∗
, Francesca Capon, PhD a, ∗ a Division of Genetics and Molecular Medicine, King's College London, London, United Kingdom
b Department of Dermatology, Hospital Sultanah Aminah, Johor Bahru, Malaysia
c Department of Dermatology, University of Glasgow, Glasgow, United Kingdom
d Department of Immunology-CDB, Hospital Clinic, Barcelona, Spain
e Department of Dermatology, Hospital Infanta Cristina, Badajoz, Spain
f Paediatric Dermatology, Our Lady's Children's Hospital, Dublin, Ireland
g Clinical Medicine, Trinity College Dublin, Dublin, Ireland
h Department of Dermatology, Dokumentationszentrum Schwerer Hautreaktionen (dZh), Universitäts-Hautklinik, Freiburg, Germany
i Department of Dermatology, Zurich University Hospital, Zurich, Switzerland
j Department of Dermatology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
k Pediatric Infectious Diseases and Immunodeficiencies Unit, Hospital Universitari Vall d'Hebron, Barcelona, Spain
l Dermatology Service, Geneva University Hospital, Geneva, Switzerland
m Department of Dermatology, Henri Mondor Hospital, Paris, France
n Department of Dermatology, Hospital Sant Joan de Deu, Esplugues, Spain
o Queen Mary University of London, Barts and The London School of Medicine and Dentistry, London, United Kingdom
| Supported by the Department of Health via the NIHR BioResource Clinical Research Facility and comprehensive Biomedical Research Centre award to Guy's and St Thomas' NHS Foundation Trust in partnership with King's College London and King's College Hospital NHS Foundation Trust. This work was funded by a Medical Research Council Stratified Medicine award (MR/L011808/1; to F.C., C.H.S., and J.N.B.). The exome sequencing of the TwinsUK cohort was funded by Wellcome Trust and European Community's Seventh Framework Programme (FP7/2007-2013) grants. The International Registry of Severe Cutaneous Adverse Reaction (RegiSCAR) Consortium was funded by unrestricted grants from the European Commission (QLRT-2002-01738), GIS-Institut des Maladies Rares and INSERM (4CH09G) in France, and a consortium of pharmaceutical companies (Bayer Vital, Boehringer Ingelheim, Cephalon, GlaxoSmithKline, MSD Sharp and Dohme, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis, and Servier). S.H. is supported by the Genetics Society and D.M.B.'s studentship is funded by the Psoriasis Association. |
|
| Disclosure of potential conflict of interest: S. Hussain is supported by the Genetics Society. D. Berki has received funding from the Psoriasis Association. J. I. Arostegui's institution has received or has grants pending from Novartis and he has received payment for delivering lectures from Novartis, and Swedish Orphan Biovitrum. L. Valeyrie-Allanore has received compensation for board membership from Jansen, MedImmune, and Boehringer Ingelheim. P. Soler-Palacin has received consultancy fees, fees for supplying expert testimony, payment for the development of educational presentations, and payment for delivering lectures from CSL Behring, and Baxter and has received or has grants pending from CSL Behring and has received compensation for travel and other meeting-related expenses from CSL Behring and Baxter. M. M. B. Seyger's institution receives compensation for board membership from Pfizer, has received or has grants pending from Pfizer, and has received payment for delivering lectures from Pfizer, as well as consultancy fees from Boehringer Ingelheim, Allmiral, and Pfizer and compensation for travel and other meeting-related expenses from Pfizer. M. Mockenhaupt receives royalties from UpToDate. J. N. Barker's institution has received funding from the National Institute for Health Research. F. Capon has grants pending from the British Skin Foundation. The rest of the authors declare that they have no relevant conflicts of interest. |
© 2014
American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 135 - N° 4
P. 1067 - avril 2015 Retour au numéro
Article précédent
- Hypersensitivity reactions to racemic calcium folinate (leucovorin) during FOLFOX and FOLFIRI chemotherapy administrations
- Alicia Ureña-Tavera, Miriam Zamora-Verduga, Ricardo Madrigal-Burgaleta, Denisse Angel-Pereira, Maria Pilar Berges-Gimeno, Emilio Alvarez-Cuesta
- Is there a risk using hypoallergenic cosmetic pediatric products in the United States?
- Carsten R. Hamann, Stewart Bernard, Dathan Hamann, Ronald Hansen, Jacob P. Thyssen
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?